Login
$CRVS
$10.81 +$0.21 (1.98%) After hours

Company Executives

Officer Age In this role Joined Source
Richard A. Miller Also a director
President, Chief Executive Officer and Chairman of the Board
75 Not stated Not stated
Leiv Lea
Chief Financial Officer
72 Since 2014
12 years
Not stated
Jeffrey S. Arcara
Senior Vice President, Chief Business Officer
57 Not stated Not stated
William B. Jones
Senior Vice President, Pharmaceutical Development
61 Since 2019
7 years
2014

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Board of Directors

From the proxy statement filed Apr 24, 2026 · updated by the 8-K of Jul 22, 2026

Directors
6
serving now
Independent
5 of 6
stated in the proxy
Average tenure
7.0 years
from year joined
CEO also chairs the board
Yes
Richard A. Miller, M.D.
Director Age On board Independent Committees Other public boards 2025 pay Source
Richard A. Miller, M.D.
75 Not stated Not independent None stated None stated Paid as CEO
Linda S. Grais, M.D., J.D.
69 2019
7 years
Independent None stated ICON plc $99,472
Andrew C. Chan, M.D., Ph.D.
Not stated Not stated Independent
Nominating and Corporate Governance Committee
None stated Not stated
Richard van den Broek
Not stated Not stated Independent None stated None stated $105,652
David S. Moore
Not stated Not stated Independent
Audit Committee Compensation Committee
None stated $182,238
Peter A. Thompson, M.D.
Not stated Not stated Independent
Nominating and Corporate Governance Committee
None stated $97,472

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

4 disclosed in the proxy filed Apr 24, 2026
OrbiMed Advisors LLC
Peter A. Thompson, M.D., a member of our Board of Directors since November 2014, is a Private Equity Partner at OrbiMed Advisors LLC
$ 2,499,856

Purchase of pre-funded warrants and common warrants in the May 2024 registered direct offering

Puissance Capital Management
Ted Wang, Ph.D., a Co-Founder, General Manager and Director of Angel Pharmaceuticals, of which the Company holds a 49.7% ownership interest, is the founder of Puissance Capital Management.
1,500,000

Purchase of shares and common warrants in the May 2024 registered direct offering

Richard A. Miller, M.D.
Richard A. Miller, M.D. is the Company’s President, Chief Executive Officer and Chairman of the Board.
1,000,000

Purchase of shares and common warrants in the May 2024 registered direct offering

William B. Jones, Ph.D.
William B. Jones, Ph.D. is the Company’s Senior Vice President, Pharmaceutical Development.
34,624

Purchase of shares and common warrants in the May 2024 registered direct offering

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support